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(6.7% ) to infection. In 2 patients (13.3%) the cause of death was unknown. Of the 10
patients who died in connection with biopsy-proven AR, 6 also had relevant CAV that
developed after the second post-HTx year. In 10 patients with moderate/severe late ARs,
but without CAV during their first episode of late AR diagnosed at 4.6± 3.0 years after
HTx, the angiogram showed relevant CAV lesions 2.4± 1.3 years after the first late AR.
The mean number of late ARs/patient/year was higher in those with angiographic CAV
that developed after the second post-HTx year than in those without CAV after >2 years
since HTx (p<0.01).
Conclusions: Late ARs are the major cause of late allograft dysfunction in children and
may also be involved in the development of CAV. Together with CAV, late ARs are the
dominant cause of death after the second post-HTx year and thus, continuous and close
rejection surveillance late after HTx is justified to improve the long-term outcome.
1089-113 Accuracy of Hemodynamic Measures by Impedance 
Cardiography in Heart Transplant Patients
Amil M. Shah, Susan Wiegers, Susan Brozena, Shashank Desai, Mariell Jessup, Andrew 
Kao, Lee Goldberg, Hospital of the University of Pennsylvania, Philadelphia, PA
Background: The ability to accurately measure cardiac index (CI) non-invasively could
reduce the frequency of surveillance right-heart catheterization (RHC) in post-transplant
patients.Impedance cardiography (IC) has been proposed as an inexpensive, accurate,
and non-invasive method of measuring hemodynamic variables. In this study we evalu-
ated the accuracy of IC in post-heart transplant patients compared to hemodynamic
measurements by Fick method at RHC.
Methods: Post-heart transplant patients undergoing routine RHC for endocardial biopsy
and measurement of hemodynamic variables were enrolled during randomly selected
clinic days. Each patient underwent IC within two hours of RHC. Fick cardiac index (CI)
was calculated using estimated resting VO2. The accuracy of the IC compared to Fick
measurement of CI was evaluated by correlation analysis using the SAS statistical soft-
ware.
Results: 55 patients were enrolled in the study. The average age was 54.6 years old and
the average months post-transplant was 28.4. 78.9% were white, 15.8% African Ameri-
can, 85.7% male. The large majority of patients did not have a significant degree of rejec-
tion on biopsy: 80.4% grade 0 or 1A, 14.3% grade 2, 5.4% grade 3A or 3B. The mean CI
as measured by IC was 2.725 (SD 0.693). The mean CI as measured by Fick method
was 2.885 (SD 0.608). Measurements by the two methods demonstrated a positive cor-
relation with a correlation coefficient(r) of 0.35 and a P value of 0.0087.
Conclusions: Our study population was predominantly white, male, middle aged, and
had a low prevalence of significant rejection. In this population, IC measures of CI do cor-
relate significantly with CI determinations by Fick method in heart transplant patients (p =
0.0087). This suggests that serial measurement of CI by impedance cardiography may
be useful. Relative drops in CI measured by IC may indicate true drops in CI as mea-
sured by Fick method and prompt invasive diagnostic testing. Further studies on the sen-
sitivity of impedance cardiography to help detect cardiac transplant rejection should be
undertaken.
1089-114 C-Reactive Protein but Not Markers of Myocardial 
Necrosis May Preclude Endomyocardial Biopsy for the 
Detection of Cardiac Allograft Rejection
Carlos T. Aguiar, Maria J. Rebocho, Miguel Abecassis, Rafael Hernandez, Nuno Jardim, 
João Figueira, Rosa Gouveia, João Q. Melo, Hospital de Santa Cruz, Carnaxide, 
Portugal
Background: Histological examination of endomyocardial biopsy (EMB) samples remains
the standard for assessing rejection after heart transplantation. However, EMB is expen-
sive, complex, time-consuming, uncomfortable and risky. The purpose of this prospective
study was to evaluate the diagnostic efficacy of C-reactive protein (CRP) and myocardial
necrosis markers (cardiac-specific troponin I: cTnI; creatine-kinase MB mass: CK-MB;
myoglobin: Myo) for the noninvasive detection of cardiac allograft rejection.
Methods: 166 EMB were performed in 41 heart transplant recipients (>10 days postoper-
atively). Blood samples obtained immediately before EMB were assayed for cTnI, CK-
MB, Myo and CRP. Biopsies were graded (0 to 4) according to ISHLT criteria. Biochemi-
cal marker levels were compared to biopsy results. ROC curves were constructed to
determine the CRP level with highest efficiency for the detection of cardiac allograft rejec-
tion grade >= 3 (discriminative value).
Results: Three EMB samples were inappropriate for histological examination. In the
remaining 163 EMB (rejection grade 0 in 110 EMB, 1 in 46, 2 in 1, 3 in 5, and 4 in 1),
there was no significant relation between cardiac allograft rejection grade and cTnI
(p=0.36), CK-MB (p=0.88), and Myo (p=0.42). In contrast, CRP levels increased signifi-
cantly with increasing rejection grade (p=0.02). CRP>=0.4 mg/dl (discriminative value)
demonstrated a 67% sensitivity, 63% specificity, 7% positive predictive value, and 98%
negative PV for the detection of cardiac allograft rejection grade >=3.
Conclusions: In contrast to myonecrosis biomarkers, CRP levels relate to EMB results.
CRP showed a very low positive and a very high negative predictive value for the detec-
tion of moderate to severe rejection. The mode of myocyte injury during rejection may not
represent irreversible cell death.
1089-116 Regional Versus Global Left Ventricular Function in 
Patients After Heart Transplantation: A Doppler 
Myocardial Imaging Study
Margret Kung, Frank Weidemann, Philip Jung, Joerg M. Strotmann, Christiane E. 
Angermann, Medizinische Poliklinik University of Würzburg, Würzburg, Germany
Decreased exercise capacity as well as myocardial structural abnormalities may occur in
patients post heart transplantation (HTx) even in the presence of normal LV systolic func-
tion. This study investigates regional longitudinal motion and deformation properties after
HTx.
Methods: 30 HTx (53,9±9,5 yrs) without evidence of acute rejection or transplant vascu-
lopathy (angiography) and mild to moderate biopsy evidence of interstitial fibrosis were
compared to 20 age-matched controls. Colour Doppler Myocardial Imaging (CDMI) data
were obtained from the mid segment of the interventricular septum and the lateral, infe-
rior and anterior wall. From each segment peak systolic velocity (parameter for motion)
and peak systolic strain rate and systolic strain (parameter for deformation) were
extracted by postprocessing the CDMI data. LV ejection fraction (EF) as a parameter of
global systolic function was assessed by MUGA scans.
Results: LVEF was normal in HTx (57±6%). Also, peak systolic velocities did not differ
(HTx: 3,0±2,9cm/s, controls 2,9±2,8cm/s;NS). However, peak systolic strain rate and
systolic strain were significantly reduced in HTx (figure). No relationship was found
between time post HTx and systolic myocardial function parameters.
Conclusion: This study implies that regional deformation parameters (strain rate and
strain) might be more sensitive for the detection of structural myocardial abnormalities in
HTx than global EF or motion parameters (velocities).
1089-117 Brain Natriuretic Peptide Levels Correspond With 
Diastolic Function Following Orthotopic Heart 
Transplantation
James O. O'Neill, Andrew T. McRae, III, Richard W. Troughton, Kenneth Ng, David O. 
Taylor, Mohammed H. Yamani, James B. Young, Randall C. Starling, Kaufman Center for 
Heart Failure, Cleveland, OH
Background: Orthotopic heart transplantation (OHT) in the early post-operative phase is
associated with restrictive physiology based on hemodynamic and echocardiographic
data. Brain natriuretic peptide (BNP) levels are elevated in patients with non-transplanted
hearts and diastolic impairment. We sought correlation between BNP levels and diastolic
function, as determined by 2 dimensional surface echocardiography, in patients 1 week
after OHT.
Methods: With informed consent, 3 ml of venous blood was drawn and BNP levels were
analyzed using a point of care assay (Biosite Diagnostics ®, San Diego, California) in
patients 1 week following OHT. Two dimensional surface echocardiography was per-
formed within 48 hours of the BNP sampling to assess left ventricular diastolic function.
Peak early (E) and late (A) velocities and early deceleration time (DT) were measured
from pulsed Doppler tracings of transmitral flow.-.
Results: Of 26 OHT patients (25 male, mean age 58 ± 10 years) included in the study,
the mean BNP level was 804 ± 459 pg/mL and the mean left ventricular ejection fraction
was 56 ± 5%. Rejection > grade 2 was present on 18 (69%) of first biopsies. There was
no correlation between E or A wave velocities and BNP levels, but there was a significant
correlation between log-transformed BNP levels and deceleration time and E/A ratio.
Conclusion: Patients have diastolic abnormalities early following OHT and the degree of
abnormality correlates with BNP levels. 
1089-118 Evaluation of the “Normal” Spectrum of Changes in 
Regional Deformation Induced by Heart 
Transplantation: An Ultrasonic Strain and Strain Rate 
Study
Elif Eroglu, Lieven Herbots, Johan Van Cleemput, Walter Droogne, Jan D'hooge, Bart 
Bijnens, Johan Vanhaecke, George R. Sutherland, University Hospital Gasthuisberg, 
Leuven, Belgium
Background: Ultrasonic Strain (S) and Strain rate imaging (SRI) indices are a more sen-
sitive measure of regional myocardial function than standard echo measurements. Thus
they might provide a new tool to define normal graft function in transplant (Tx) pts and to
detect early changes due either to rejection, vasculopathy or drug therapy. Prior to inves-
tigating the role of SRI in detecting such abnormalities, normal Tx S/SR values must be
established as graft regional function could be altered by ischemic time, cardioplegic
arrest or age mismatch.
Methods: 57 pts (age 36±12 y; post Tx 5.5±3 y) were studied. All had normal coronary
angiography, LV ejection fraction, right heart pressure and negative endomyocardial
biopsy. SRI data was acquired from the base, mid and apex of anterior, inferior, septal,
Mean value ± SD Correlation with LnBNP P value
E wave velocity cm/sec 91 ± 22 0.01 NS
A wave velocity cm/sec 43 ± 22 -0.02 NS
E/A ratio 2.2 ± 0.8 0.41 <0.01
Deceleration time ms 167 ± 22 -0.40 <0.05
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lateral LV and RV free walls (RVFW). 29 age-matched healthy subjects served as Con-
trols.
Results: S/SR values were similar in Tx and Controls except in the septum and RVFW.
Unlike the normal base-apex myocardial velocity gradient, S/SR were homogenous
throughout all walls for Tx and Controls. Because of this homogeneity, values were aver-
aged for every wall. 
*p<0.005
Conclusion: SRI is a robust and reproducible technique for the quantification of regional
myocardial function in Tx pts. Although global systolic function indices were normal, long
axis peak systolic S/SR were reduced in the septum and RVFW post Tx. These findings
must be taken into account when using SRI to detect further abnormalities in Tx hearts.
1089-119 Pentoxifylline Protects Allogenic Transplanted Hearts
Nour Eddine El Mokhtari, Alexander Reinecke, Bettina Dresske, Markus Lins, Dietmar 
Krueger, Andreas Tiroke, Stefan Hirt, Rudiger Simon, University of Kiel, Kiel, Germany
Background:
We studied whether pentoxifylline, an important modulator of proinflammatory and
proapoptotic cytokines, attenuates allograft rejection in an experimental model of hetero-
topic heart transplantation.
Methods: 
In age matched male rats, different transplantational settings were performed. Hearts
from Fisher 344 rats were abdominally transplanted to Wistar Kyoto rats (WKY) receiving
daily intraperitoneally injections of pentoxifylline (25mg/kg BW) or vehicle, respectively.
Additionally, syngenic transplantations from WKY to vehicle treated WKY served as con-
trols.
For investigating allograft survival, heartbeats were daily controlled by palpation (n=15 for
each setting) up to 150 days after transplantation.
For investigating rejection and apoptotic cell death in the allografts, all specimens were
graded according to the International Society for Heart and Lung Transplantation (ISHLT)
Criteria and the number of apoptotic cells per left ventricular cross-section derived from
TUNEL assays performed at day 3, 6, and 15 after transplantation (n=6 for each time
point and setting).
Results:
Comparted to vehicle treatment (21±5 days), pentoxifylline treatment significantly
(p<0.01) improved mean allograft survival time (70± 24 days), whereas none of the syn-
genically transplanted WKY hearts were rejected throughout the protocol. Accordingly,
pentoxiffylline treatment showed a highly significant (p<0.001) reduction of the time-
dependent increase in apoptotic cell death (up to a twenty fold reduction at day 15).
Conclusions:
This study showed for the first time that pentoxifylline treatment could be an effective tool
for preventing rejection after heart transplantation. This finding could be of great clinical
importance.
ORAL CONTRIBUTIONS
821 Heart Failure: Beta-Blockers
Monday, March 08, 2004, 2:00 p.m.-3:30 p.m.
Morial Convention Center, Room 254
2:00 p.m.
821-1 Should Beta-Blockers Be Used Before Angiotensin 
Converting Enzyme Inhibitors in Patients With Chronic 
Heart Failure? Meta-Analysis of the Prognostic Benefit 
Conferred by Beta-Blockers in Patients Not Receiving 
ACE Inhibitors
Henry Krum, Steven Haas, Jalal Ghali, Edward Gilbert, Phillipe Lechat, Mary-Ann Lukas, 
Milton Packer, Ellen Roecker, Patricia Verkenne, Hans Wedel, John Wikstrand, The Beta-
Blockers in Heart Failure Collaborative Group, Monash University, NHMRC CCRE in 
Therapeutics, Melbourne Victoria, Australia
Background: Beta-blockers (BBs) confer significant prognostic benefit in patients (pts)
with chronic heart failure (CHF), however major trials have thus far studied BBs mainly in
addition to ACE inhibitors (ACEi) as background therapy. The magnitude of the prognos-
tic benefit of BB’s in the absence of ACEi has not as yet been determined.
Methods: We performed a meta-analysis of all available, large (n>500), placebo (PBO)-
controlled studies of BBs in patients with CHF. Trials were identified via Medline literature
searches, from meeting abstracts and contact with study organisations. Results were
pooled using the Mantel-Haenszel method.
Results: The impact of beta-blocker therapy on all-cause mortality in CHF, in the
absence (4.3%) and presence (95.7%) of ACEi therapy at baseline, is shown in the Table.
The overall relative risk (RR) of 0.67 (0.43-1.04) for BBs in the absence of ACEi therapy
at baseline appears to exceed that for ACEi studied vs PBO in the pre-BB era of CHF
(0.77 [0.67 - 0.88]). 
Conclusions: The magnitude of the prognostic benefit conferred by BBs in the absence
of ACEi exceeds those of ACEi in CHF. These data therefore support the early introduc-
tion of BBs to pts with CHF. Prospective studies directly comparing BBs and ACEi as first-
line agents are required to definitively address this issue.
*Garg, Yusuf. JAMA 1995;273:1450-1456.
2:15 p.m.
821-2 Characteristics of Heart Failure Patients in Clinical 
Practice: How Do They Relate to Ejection Fraction?
Barry M. Massie, Jeanenne J. Nelson, Mary Ann Lukas, Sandra R. Lottes, Barry 
Greenberg, Michael B. Fowler, Edward M. Gilbert, William T. Abraham, Joseph A. 
Franciosa, and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background and methods: Clinical trials usually categorize heart failure (HF) patients
dichotomously by left ventricular ejection fraction (EF). In the community setting patient
characteristics and physician practices vary across the entire EF range. From the Coreg
Heart Failure Registry (COHERE) of 4,280 patients initiating carvedilol for HF in the com-
munity we related baseline EF quartiles to patient characteristics, treatments, and out-
comes.
Results: Findings are in the table. Age, proportions of women, hypertensives or diabet-
ics, and baseline BP all increased with increasing EF. Patients with lower EF had higher
NYHA class and more HF hospitalizations in the prior year. ACE inhibitor use declined
with increasing EF as did achievement of recommended maximal doses of carvedilol,
and total daily dose was lowest in EF >40% group (26 ± 21 mg) and highest in the EF
<20% group (33 ± 23 mg). Symptoms improved more often in the lower EF groups. Hos-
pitalizations for HF were reduced during follow-up vs the prior year in all groups, with a
greater decline in lower EF groups. Though mortality at 1 yr was highest in the lower EF
quartiles, apparent statistically significant differences became not significant when
adjusted for age, gender, co-morbidities and other baseline characteristics. 
Conclusion: These observations indicate that the characteristics and treatment of HF 
patients initiating beta-blockers in the community vary in a graduated, not dichotomous 
manner, across the range of EF.
Tx Controls
Walls SR (1/s) S (%) SR (1/s) S (%)
septum
lateral
anterior
inferior
RVFW
1,3±0,4*
1,9±0,9
1,8±0,7
1,6±0,6
2,1±1,7*
16±7*
18±8
18±7
19±7
21±9*
1,8±0.5
1,8±0.8
1,8±0.9
1,7±0.5
3,3±1.3
23±6
18±6
19±5
21±4
42±13
No ACEi ACEi
PBO BB RR (95% CI) PBO BB RR (95% CI)
Events n Events n Events n Events n
CIBIS I 4 29 2 34 0.43 (0.08 – 
2.16)
63 292 51 286 0.83 (0.59 – 1.15)
CIBIS II 8 46 12 54 1.28 (0.57 – 
2.85)
220 1274 144 1273 0.66 (0.54 – 0.80)
COPERNICUS 11 32 6 33 0.53 (0.22 – 
1.26)
179 1101 124 1123 0.68 (0.55 – 0.84)
MERIT-HF 12 76 9 92 0.62 (0.28 – 
1.39)
205 1925 136 1898 0.67 (0.55 – 0.83)
US Carvedilol 2 19 0 41 0.10 (0.00 – 
1.89)
29 379 22 655 0.44 (0.26 – 0.75)
TOTAL 37 202 29 254 0.67 (0.43 – 
1.04)
696 4971 477 5235 0.67 (0.60 – 0.75)
Patient Characteristic/outcome Quartile 1
EF_ 20% 
(n=1039)
Quartile 
2
EF 21-
30%
(n=1304)
Quartile 3
EF 31-
40%
(n=1107)
Quartile 
4
EF > 
40%
(n=700)
p value (for the 
distribution)
LVEF (%) 17±3 27±3 36±3 52±9 <0.001
Age (yr) 65±13 66±13 67±12 68±13 <0.001
Women 30% 33% 32% 46% <0.001
Prior myocardial infarction 38% 45% 45% 34% <0.001
History of hypertension 54% 54% 60% 66% <0.001
Diabetes 29% 32% 32% 35% P=0.035
NYHA class III or IV 49% 41% 32% 28% <0.001
Systolic BP (mm Hg) 122+20 128+20 131+20 135+21 <0.001
On ACE inhibitor 80% 78% 75% 66% <0.001
On diuretic 87% 76% 71% 70% <0.001
On digoxin 73% 63% 50% 39% <0.001
Carvedilol titrated to _25 mg 
BID
49% 47% 47% 33% <0.001
NYHA class improved 36% 32% 26% 22% <0.001
NYHA class worsened 10% 11% 11% 8% P=0.28
HF hospitalization, prior yr 40% 28% 23% 19% <0.001
HF hospitalization, during 1 yr 
follow-up
13%* 12%* 10%* 11%* P=0.25
12-month mortality (unadjusted) 11.0% 9.0% 6.6% 6.8% <0.01
* p <0.001 vs prior yr
